Abstract
The risk of severe COVID-19 disease requiring hospitalization with extensive oxygen supply was compared among infected cases during two calendar periods when Delta and Omicron, respectively, were the dominating virus variants in Scania county, Sweden. Adjustments were made for differences among cases in comorbidities, prior infection, vaccination status, age and sex. Markedly lower risks were observed from Omicron among the vaccinated in the present study. The risk of severe disease was also lower for unvaccinated during Omicron than during Delta, but remained high among older people and middle-aged males with comorbidities. Efforts to increase vaccination uptake across countries, populations and subgroups should thus remain a public health priority.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Swedish Research Council (VR; grant numbers 2019-00198 and 2021-04665), Swedens Innovation Agency (Vinnova; grant number 2021-02648) and by internal grants for thematic collaboration initiatives at Lund University held by JB and MI. FK is supported by grants from the Swedish Research Council and Governmental Funds for Clinical Research (ALF), and CB is supported by Swedish Research Council for Health, Working life and Welfare (Forte; grant number 2020-00962). The funders played no role in the design of the study, data collection or analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Swedish Ethical Review Authority (2021-00059).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Aggregated surveillance data from the present study will be made available at a web page administrated by the Scania county council.
https://sodrasjukvardsregionen.se/kliniskastudier/covid-vacciner-skyddseffekt/
